Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Steven Petrovas

Pain Medicine Grand Rapids, MI Medical Doctor

NPI 1568775443 CMS profile 161739

1900 Wealthy St Se Ste 290, Grand Rapids, MI 49506

Open in the dashboard

General payments

$1,927

55 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Steven Petrovas of Grand Rapids, MI is reported in the CMS Open Payments database as having received $1,927 across 55 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 47th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $320 4
2023 General $56 3
2022 General $168 4
2021 General $337 9
2020 General $254 9
2019 General $792 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Petrovas
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Steven Petrovas were reported at $0. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Steven Petrovas Pain Medicine median Middle half National median
2019 $792 $498 $126–$1,682 $163
2020 $254 $284 $80–$910 $114
2021 $337 $399 $112–$1,219 $132
2022 $168 $455 $137–$1,484 $149
2023 $56 $484 $128–$1,495 $160
2024 $320 $498 $131–$1,540 $164
2025 $0 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Boston Scientific Corporation $512 11 payments
  2. Nevro Corp. $481 7 payments
  3. Abbott Laboratories $154 1 payment
  4. Medtronic, Inc. $140 1 payment
  5. Nalu Medical, Inc. $135 1 payment
  6. Pfizer Inc. $128 15 payments
  7. RedHill Biopharma Inc. $96 4 payments
  8. Merck Sharp & Dohme Corporation $70 4 payments
  9. US WorldMeds, LLC $63 3 payments
  10. Metrex Research, LLC $55 1 payment
  11. Other $93 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,907 54 payments
  2. Education $20 1 payment
Products named General payments · program years 2019–2024
  1. Senza Spinal Cord Stimulation System $481 7 payments
  2. WaveWriter Alpha Prime 16 $326 5 payments
  3. Proclaim Family of SCS IPGs $154 1 payment
  4. INTELLIS $140 1 payment
  5. Nalu Neurostimulation System $135 1 payment
  6. LYRICA $128 15 payments
  7. EMBEDA $115 12 payments
  8. GENERAL - PAIN MANAGEMENT $109 1 payment
  9. FLECTOR PATCH $102 11 payments
  10. Movantik $96 4 payments
  11. Other $376 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,431

Median for Anesthesiology: 322

Drug cost

$29,037

Median for Anesthesiology: $8,738

Branded share of claims

33.8%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Movantik Naloxegol Oxalate Brand 25 $10,117
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 280 $4,476
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 160 $3,267
Diclofenac Sodium Generic 66 $1,943
Lidocaine Generic 27 $1,861
Gabapentin Generic 169 $1,675
Pregabalin Generic 151 $1,666
Tizanidine Hcl Generic 86 $867
Cyclobenzaprine Hcl Generic 100 $487
Duloxetine Hcl Generic 58 $486

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 94 billing codes

Paid by Medicare

$63,116

Of which drugs: $37

Medicare patients

385

Average age 70

Services billed

1,085

217 women, 168 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Diabetes 42%
Depression 35%
Ischemic heart disease 34%
COPD 33%
Chronic kidney disease 29%
Heart failure 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 27 400 $36

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

55 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record